Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Research & Development (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Research & Development for 6 consecutive years, with $31.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 51.63% to $31.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $125.9 million, a 84.09% increase, with the full-year FY2025 number at $125.9 million, up 84.09% from a year prior.
  • Research & Development was $31.5 million for Q4 2025 at Janux Therapeutics, down from $34.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $34.7 million in Q2 2025 to a low of $1.9 million in Q1 2021.
  • A 5-year average of $16.4 million and a median of $14.5 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 1033.91% in 2021, then decreased 20.69% in 2023.
  • Janux Therapeutics' Research & Development stood at $11.2 million in 2021, then surged by 38.19% to $15.4 million in 2022, then fell by 20.69% to $12.2 million in 2023, then surged by 69.97% to $20.8 million in 2024, then surged by 51.63% to $31.5 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Research & Development are $31.5 million (Q4 2025), $34.6 million (Q3 2025), and $34.7 million (Q2 2025).